Jaime Ungo, MD
Pulmonary Disease · Tupelo, MSNPI 1275599656
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), education and speaking fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Intuitive Surgical at 37.2% of the total. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 720 payments — averaging $40.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- GSK$5K
- AstraZeneca$4K
- Boehringer Ingelheim$1K
- Harmony Biosciences LLC$826
- Insmed, Inc.$568
- plus $6K from 41 others
What the payments were for
- Consulting fees$1,7006%
- Speaking & faculty fees$2,92510%
- Travel & lodging$1,1524%
- Food & beverage$14,09249%
- Education$9,18132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,049 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $261,705 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $102,331 |
| Breo ElliptaFluticasone/Vilanterol | 87 | $44,924 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $24,657 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $14,121 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $13,776 |
| Spiriva RespimatTiotropium Bromide | 25 | $12,710 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $9,881 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,811 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,239 |
| Varenicline Tartrate | 13 | $4,057 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $2,949 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,452 |
| Armodafinil | 13 | $838 |
| Ventolin HfaAlbuterol Sulfate | 15 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,213 | $288,19161 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $5,277 | $161,376250 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,326 | $34,53776 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Tupelo
- William EdmonsonTupelo$15K
- Paul PerryTupelo$13K
- Kevin HarbourTupelo$13K
- Robert StewartTupelo$10K
- David WittyTupelo$7K
- Ryan SessumsTupelo$4K
- Jose Henao CorreaTupelo$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.